Lippi G, Cervellin G, Franchini M, Favaloro EJ (2010). "Biochemical markers for the diagnosis of venous thromboembolism: the past, present and future". J. Thromb. Thrombolysis. 30 (4): 459–71. doi:10.1007/s11239-010-0460-x. PMID20213258.
Wu, C. -H.; Yang, R. -L.; Huang, S. -Y.; Li, H. -Z.; Wang, K. -Y.; Yang, D. -H.; Yan, X. -H.; Xue, X. -H.; Wu, S. -Y. (August 2011). "Analysis of thrombin-antithrombin complex contents in plasma and hematoma fluid of hypertensive intracerebral hemorrhage patients after clot removal: TAT in ICH patients". European Journal of Neurology. 18 (8): 1060–1066. doi:10.1111/j.1468-1331.2010.03336.x. PMID21244583.
Merlini PA, Ardissino D (1995). "Laboratory Measurement of Thrombin Activity--What Every Clinician Scientist Needs to Know". J Thromb Thrombolysis. 2 (2): 85–92. doi:10.1007/BF01064374. PMID10608009.
Hellgren M (April 2003). "Hemostasis during normal pregnancy and puerperium". Semin Thromb Hemost. 29 (2): 125–30. doi:10.1055/s-2003-38897. PMID12709915.
Douxfils J, Morimont L, Bouvy C (November 2020). "Oral Contraceptives and Venous Thromboembolism: Focus on Testing that May Enable Prediction and Assessment of the Risk". Semin Thromb Hemost. 46 (8): 872–886. doi:10.1055/s-0040-1714140. PMID33080636.
Skouby, Sven O.; Sidelmann, Johannes J. (2 July 2020). "Menopausal Hormone Therapy (MHT) and Venous Thrombosis". Managing the Menopause. Cambridge University Press. pp. 223–233. doi:10.1017/9781108869102.023.
Ockrim JL, Lalani EN, Kakkar AK, Abel PD (August 2005). "Transdermal estradiol therapy for prostate cancer reduces thrombophilic activation and protects against thromboembolism". J Urol. 174 (2): 527–33, discussion 532–3. doi:10.1097/01.ju.0000165567.99142.1f. PMID16006886.
Kohli, M.; Alikhan, M. A.; Spencer, H. J.; Carter, G. (15 July 2004). "Phase I trial of intramuscular estradiol valerate (I/M-E) in hormone refractory prostate cancer". Journal of Clinical Oncology. 22 (14 suppl): 4726–4726. doi:10.1200/jco.2004.22.90140.4726. eISSN1527-7755. ISSN0732-183X.
Lippi G, Cervellin G, Franchini M, Favaloro EJ (2010). "Biochemical markers for the diagnosis of venous thromboembolism: the past, present and future". J. Thromb. Thrombolysis. 30 (4): 459–71. doi:10.1007/s11239-010-0460-x. PMID20213258.
Wu, C. -H.; Yang, R. -L.; Huang, S. -Y.; Li, H. -Z.; Wang, K. -Y.; Yang, D. -H.; Yan, X. -H.; Xue, X. -H.; Wu, S. -Y. (August 2011). "Analysis of thrombin-antithrombin complex contents in plasma and hematoma fluid of hypertensive intracerebral hemorrhage patients after clot removal: TAT in ICH patients". European Journal of Neurology. 18 (8): 1060–1066. doi:10.1111/j.1468-1331.2010.03336.x. PMID21244583.
Merlini PA, Ardissino D (1995). "Laboratory Measurement of Thrombin Activity--What Every Clinician Scientist Needs to Know". J Thromb Thrombolysis. 2 (2): 85–92. doi:10.1007/BF01064374. PMID10608009.
Hellgren M (April 2003). "Hemostasis during normal pregnancy and puerperium". Semin Thromb Hemost. 29 (2): 125–30. doi:10.1055/s-2003-38897. PMID12709915.
Douxfils J, Morimont L, Bouvy C (November 2020). "Oral Contraceptives and Venous Thromboembolism: Focus on Testing that May Enable Prediction and Assessment of the Risk". Semin Thromb Hemost. 46 (8): 872–886. doi:10.1055/s-0040-1714140. PMID33080636.
Ockrim JL, Lalani EN, Kakkar AK, Abel PD (August 2005). "Transdermal estradiol therapy for prostate cancer reduces thrombophilic activation and protects against thromboembolism". J Urol. 174 (2): 527–33, discussion 532–3. doi:10.1097/01.ju.0000165567.99142.1f. PMID16006886.
Kohli, M.; Alikhan, M. A.; Spencer, H. J.; Carter, G. (15 July 2004). "Phase I trial of intramuscular estradiol valerate (I/M-E) in hormone refractory prostate cancer". Journal of Clinical Oncology. 22 (14 suppl): 4726–4726. doi:10.1200/jco.2004.22.90140.4726. eISSN1527-7755. ISSN0732-183X.